Skip to main content
SpringerLink
Log in

Faropenem Medoxomil

A0026, BAY 56-6854, BAY 566854, Faropenem Daloxate, SUN 208, SUN A0026

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Replidyne Inc. Replidyne Announces 2006 Fourth Quarter and Year-End Earnings. Media Release: 28 Feb 2007. Available from: URL: http://www.replidyne.com

    Google Scholar 

  2. Replidyne Inc. Replidyne In-licenses Faropenem Daloxate. Media Release: 17 Aug 2004. Available from: URL: http://www.replidyne.com

    Google Scholar 

  3. Replidyne Inc, Forest Laboratories Inc. Replidyne and Forest End Faropenem Collaboration. Media Release: 6 Feb 2007. Available from URL: http://www.replidyne.com

    Google Scholar 

  4. Forest Laboratories Inc, Replidyne Inc. Forest Laboratories Announces Termination of Agreement for Faropenem. Media Release: 6 Feb 2007. Available from URL: http://www.frx.com

    Google Scholar 

  5. Replidyne Inc, Forest Laboratories Holdings Ltd. Replidyne and Forest Laboratories Announce Faropenem Medoxomil Licensing Agreement. Media Release: 13 Feb 2006. Available from URL: http://www.replidyne.com

    Google Scholar 

  6. Daiichi Sankyo Inc. U.S. Subsidiaries Join Together to Form Daiichi Sankyo, Inc. Media Release: 3 Apr 2006. Available from URL: http://www.daiichisankyo-us.com

    Google Scholar 

  7. Replidyne Inc. Replidyne Defines Preliminary Phase III Development Plan for Faropenem. Media Release: 27 Mar 2007. Available from URL: http://www.replidyne.com

    Google Scholar 

  8. Replidyne Inc. Replidyne Submits New Drug Application (NDA) for Orapem(TM) (Faropenem Medoxomil) to U.S. Food and Drug Administration. Media Release: 9 Jan 2006. Available from URL: http://www.replidyne.com

    Google Scholar 

  9. Forest Laboratories Inc, Replidyne Inc. Replidyne and Forest Laboratories Announce FDA Acceptance for Review of New Drug Application for Oral Antibiotic Faropenem Medoxomil. Media Release: 23 Feb 2006. Available from URL: http://www.frx.com

    Google Scholar 

  10. Replidyne Inc. Replidyne Announces Second Quarter Results. Media Release: 1 Aug 2006. Available from URL: http://www.replidyne.com

    Google Scholar 

  11. Replidyne Inc. Replidyne Phase II Pediatric Trial Meets Primary Objective. Media Release: 6 Mar 2007. Available from URL: http://www.replidyne.com

    Google Scholar 

  12. Replidyne Inc. Replidyne Completes Phase 2 Trial Enrollment. Media Release: 20 Dec 2006. Available from URL: http://www.replidyne.com

    Google Scholar 

  13. Deisseroth AB, Hanania EG, Fu S. Genetic therapy of human disease. Bone Marrow Transplantation 15 (Suppl. 1): 285–290, 1995

    Google Scholar 

  14. Voith B, Schuehly U, Voigt U, et al. Influence of food intake on the pharmacokinetics, safety and tolerability of a single dose of faropenem daloxate. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy: 16, 17 Sep 2000

    Google Scholar 

  15. Schmidt A, voith B, Dalhoff A. No evidence of active metabolites of faropenem. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy: 23 (plus poster), 22 Sep 2001

    Google Scholar 

  16. Voith B, Wilding I, Wray A, et al. Absorption of faropenem daloxate delivered locally to different sites of the gastrointestinal tract by an Enterion capsule. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy: 23 (plus poster), 22 Sep 2001

    Google Scholar 

  17. Gill SC, Tosiello R. Pharmacokinetics of faropenem following oral administration of faropenem medoxomil in association with thorough QT/QTc evaluation. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy: 29 (plus poster) abstr. A-1942, 27 Sep 2006

    Google Scholar 

  18. Tosiello R, Sprenger C, Echols R, et al. A thorough ECG study of faropenem medoxomil compared to placebo and a positive control. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy: 24–25 (plus poster) abstr. A1111, 27 Sep 2006

    Google Scholar 

  19. Nakashima M, Umemura K. Pharmacokinetics of SUN208 in healthy male volunteers. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 136, 17 Sep 1995

    Google Scholar 

  20. Nagelschmitz J, Koch M, Heizmann WR, et al. Effect of multiple dose treatments with faropenem daloxate in comparison to amoxicillin/clavulanic acid on the normal fecal and oropharyngeal flora of healthy subjects. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy: 22 (plus poster), 22 Sep 2001

    Google Scholar 

  21. Marbury T, Roesch B, Corrado M, et al. A double-blind, randomized, dose ranging study to evaluate the safety of faropenem medoxomil at 300 or 600 mg BID for seven days in healthy volunteers. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy: 396 (plus poster) abstr. L-480, 17 Sep 2007

    Google Scholar 

  22. Kowalsky S, Upchurch J, Rosemore M, et al. Prospective, randomized, double-blind, three-armed, multicenter, comparative trial to evaluate the efficacy and safety of faropenem daloxate 300 mg PO, BID for 7 days versus faropenem daloxate 300 mg PO, BID for 10 days versus cefuroxime axetil 250 mg PO, BID for 10 days in the treatment of acute bacterial sinusitis. Study 100288. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 389 (plus poster) abstr. L-575, Dec 2005

    Google Scholar 

  23. Echols R, Tlili N, Nikolaidis P, et al. Prospective, randomized, double-blind, multinational, multicenter clinical trial comparing the efficacy and safety of faropenem daloxate 300 mg PO, BID for 7 days with cefuroxime axetil for 7 days (250 mg BID) in the treatment of patients with acute bacterial sinusitis. Study 10186. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 388–389, Dec 2005

    Google Scholar 

  24. Siegert R, Berg O, Gehanno P, et al. Faropenem daloxate vs. cefuroxime axetil in the treatment of acute sinusitis. Clinical Microbiology and Infection 8 (Suppl. 1): 327, Apr 2002

    Google Scholar 

  25. Dhillon G, Williams H, Corrado M, et al. A phase II double-blind, randomized trial comparing faropenem medoxomil at 300 mg BID for seven days and 600 mg BID for five days in subjects with acute maxillary sinusitis diagnosed by antral tap. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy: 396 (plus poster) abstr. L-481, 17 Sep 2007

    Google Scholar 

  26. Echols R, Schürmann D. A multicenter, multinational, prospective, randomized, double-blind study to compare the efficacy and safety of faropenem daloxate 300 mg PO BID for 10 days with co-amoxiclav 500/125 mg PO TID for 10 days in the treatment of adult patients with community-acquired pneumonia. Study 10189. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 393–394 (plus oral presentation) abstr. L708, Dec 2005

    Google Scholar 

  27. Drehobl M, Patel T, Echols R. Prospective, randomized, double-blind study comparing faropenem daloxate 300 mg PO BID for 10 days with cefpodoxime 200 mg PO BID for 14 days in the treatment of patients with community-acquired pneumonia. Study 100290. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 388 (plus poster) abstr. L-571, Dec 2005

    Google Scholar 

  28. Walker G, Upchurch J, Fogarty C, et al. Prospective, randomized, double-blind study comparing faropenem daloxate 300 mg PO BID for 5 days with azithromycin for 5 days (500 mg PO OD on day 1, then 250 mg PO OD on day 2 through 5) in the treatment of patients with acute exacerbation of chronic bronchitis. Study 100291. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 389 (plus poster) abstr. L-576, Dec 2005

    Google Scholar 

  29. Corrado M, Echols R. A multinational, multi-centre, prospective, double-blind, parallel group, randomized study of faropenem daloxate (BAY 56-6854) oral tablets compared to clarithromycin oral tablets, in the treatment of acute exacerbation of chronic bronchitis. Study 10187. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 388 (plus poster) abstr. L-572, Dec 2005

    Google Scholar 

  30. Richard G, Mazzone F, Drehobl M, et al. Prospective, randomized, double-blind study comparing faropenem daloxate 300 mg PO BID for 5 days with trimethoprim/sulfamethoxazole 160/800 mg PO bid for 5 days in treatment of patients with acute, uncomplicated lower urinary tract infections. Study 100286. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 411, Dec 2005

    Google Scholar 

  31. Davis A, Heaton K, Huck W, et al. Prospective, randomized, double-blind, multi-center trial to compare the efficacy and safety of faropenem daloxate 300 mg PO BID for 5 days versus penicillin VK 500 mg PO TID for 10 days in the treatment of adults and adolescents with acute Streptococcus pyogenes tonsillitis/pharyngitis. Study 100293. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 392, Dec 2005

    Google Scholar 

  32. Corrado M, Shemer A, Echols R. Prospective, randomized, double-blind, double-dummy, multi-centre comparative trial to evaluate the efficacy and safety of faropenem daloxate 300 mg PO BID for 7 days vs co-amoxiclav 625 mg PO TID for 7 days in the treatment of uncomplicated skin and skin structure infections. Study 10190. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 402 (plus poster) abstr. L-1572, Dec 2005

    Google Scholar 

  33. Huck W, Heaton K, Elliott S, et al. Prospective, randomized, double-blind, multicenter, comparative trial to evaluate the efficacy and safety of faropenem daloxate 300 mg PO BID for 7 days versus cephalexin 500 mg PO BID for 7 days in the treatment of uncomplicated skin and skin structure infections. Study 100292. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 402 (plus poster) abstr. L-1571, Dec 2005

    Google Scholar 

  34. Schuehly U, Voith B, Voigt U, et al. Investigation of a potential pharmacokinetic interaction between furosemide and faropenem daloxate after concomitant single-dose administration. Clinical Microbiology and Infection 7 (Suppl. 1): 274–275, 2001

    Google Scholar 

  35. Voith B, Schuehly U, Ruf T, et al. Influence of concomitant administration of probenecid on the safety, tolerability, and pharmacokinetics of a single dose of faropenem daloxate. Clinical Microbiology and Infection 7 (Suppl. 1): 274, 2001

    Google Scholar 

  36. Voith B, Schuehly U, Ruf T, et al. Influence of a pre- and cotreatment with Maalox (Rm) 70 on safety, tolerability, and pharmacokinetics of a single dose of faropenem daloxate. Clinical Microbiology and Infection 7 (Suppl. 1): 274, 2001

    Google Scholar 

  37. Heine H, Rubino CM, Basett J, et al. Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine-Bacil-lus anthracis inhalation post-exposure prophylaxis model. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy: 34 (plus poster) abstr. A-1435, 17 Sep 2007

    Google Scholar 

  38. Heine HS, Miller L, Bassett J, et al. Activity of faropenem against Bla1 and Bla2 beta-lactamase producing strains of Bacillus anthracis. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy: 178 (plus poster) abstr. E-226, 27 Sep 2006

    Google Scholar 

  39. Young C, Critchley IA, Janjic N. Activity of faropenem against multi-drug resistant Streptococcus pneumoniae identified in phase III respiratory clinical trials and correlation with clinical microbiological success. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy: 178 (plus poster) abstr. E-224, 27 Sep 2006

    Google Scholar 

  40. Clawson Stone K, Dagan R, Arguedas A, et al. Activity of faropenem against middle ear fluid pathogens from children with acute otitis media in Costa Rica and Israel. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy: 178 (plus poster) abstr. E-225, 27 Sep 2006

    Google Scholar 

  41. Singh S, Echols R. Prospective, multi-center, nonblind, uncontrolled trial to evaluate the efficacy and safety of faropenem daloxate 300 mg PO, BID for 7 days in the treatment of acute bacterial sinusitis. Study 100287. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 389 (plus poster) abstr. L-574, Dec 2005

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Faropenem Medoxomil. Drugs R&D 9, 115–124 (2008). https://doi.org/10.2165/00126839-200809020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200809020-00005

Keywords

Search

Navigation